Neoleukin Therapeutics, Inc. Banner Image

Neoleukin Therapeutics, Inc.

  • Ticker NLTX
    Exchange NASDAQ More
  • Industry Drug Manufacturers - Other More
  • Sector Healthcare More
Neoleukin Therapeutics, Inc. Logo Image
  • 11-50 Employees
  • Based in Seattle, Washington
Neoleukin is a biopharmaceutical company creating next generation immunotherapies for cancer, inflammation and autoimmunity using de novo protein design technology. Neoleukin uses sophisticated computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins. Neoleukin’s lead product candidateMore, NL-201, is a combined IL-2 and IL-15 agonist designed to improve tolerability and activity by eliminating the alpha receptor binding interface.
4.8 / 5.0 (138)

Neoleukin Therapeutics, Inc. reports have an aggregate usefulness score of 4.8 based on 138 reviews.

Neoleukin Therapeutics, Inc.

Most Recent Annual Report

Neoleukin Therapeutics, Inc.
MOST RECENT 2022 Annual Report and Form 10K

Older/Archived Annual Reports

Neoleukin Therapeutics, Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!